Avelumab + axitinib vs sunitinib in patients (pts) with advanced renal cell carcinoma (aRCC): Final overall survival (OS) analysis from the JAVELIN Renal 101 phase 3 trial.
Motzer R, Penkov K, Uemura H, Campbell M, Kollmannsberger C, Lee J, Venugopal B, Van Den Eertwegh A, Negrier S, Gurney H, Albiges L, Berger R, Haanen J, Rini B, Larkin J, Schmidinger M, Sandner R, Wang J, Di Pietro A, CHOUEIRI T. Avelumab + axitinib vs sunitinib in patients (pts) with advanced renal cell carcinoma (aRCC): Final overall survival (OS) analysis from the JAVELIN Renal 101 phase 3 trial. Journal Of Clinical Oncology 2024, 42: 4508-4508. DOI: 10.1200/jco.2024.42.16_suppl.4508.Peer-Reviewed Original ResearchAdvanced renal cell carcinomaPD-L1+ tumorsProgression-free survivalOverall survivalJAVELIN RenalPD-L1Sunitinib armSafety profileFollow-upUntreated advanced renal cell carcinomaImmune checkpoint inhibitorsPD-(L)1 inhibitorsOverall populationSecond-line therapyMedian follow-upFirst-line treatmentPhase 3 trialRenal cell carcinomaInhibitor combination treatmentLong-term efficacySP263 assayCheckpoint inhibitorsPD-(L)1Data cutoffSecond-line